These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12781431)

  • 21. Radiation therapy alone in elderly with early stage non-small cell lung cancer.
    San José S; Arnaiz MD; Lucas A; Navarro V; Serrano G; Zaderazjko M; Jeremic B; Guedea F
    Lung Cancer; 2006 May; 52(2):149-54. PubMed ID: 16516336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy alone.
    Jeremić B; Milicić B; Dagović A; Acimović L; Milisavljević S
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1112-9. PubMed ID: 16682148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
    Maguire PD; Marks LB; Sibley GS; Herndon JE; Clough RW; Light KL; Hernando ML; Antoine PA; Anscher MS
    J Clin Oncol; 2001 Feb; 19(3):705-11. PubMed ID: 11157021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
    Firat S; Byhardt RW; Gore E
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
    Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
    Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    Radiother Oncol; 1999 May; 51(2):141-5. PubMed ID: 10435805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule.
    Valeriani M; Marinelli L; Reverberi C; De Sanctis V; Mollo D; Nicosia L; Osti MF
    Radiol Med; 2019 Jan; 124(1):58-64. PubMed ID: 30178173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
    Jeremić B; Milicić B; Acimović L; Milisavljević S
    J Clin Oncol; 2005 Oct; 23(28):6873-80. PubMed ID: 16192579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
    Timmerman R; McGarry R; Yiannoutsos C; Papiez L; Tudor K; DeLuca J; Ewing M; Abdulrahman R; DesRosiers C; Williams M; Fletcher J
    J Clin Oncol; 2006 Oct; 24(30):4833-9. PubMed ID: 17050868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center.
    Bush DA; Cheek G; Zaheer S; Wallen J; Mirshahidi H; Katerelos A; Grove R; Slater JD
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):964-8. PubMed ID: 23845845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.
    Haussmann J; Tamaskovics B; Bölke E; Djiepmo-Njanang FJ; Kammers K; Corradini S; Hautmann M; Ghadjar P; Maas K; Schuler PJ; Hoffmann TK; Lammering G; Budach W; Matuschek C
    Strahlenther Onkol; 2019 Dec; 195(12):1041-1049. PubMed ID: 31586229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
    Nyman J; Bergman B; Mercke C
    Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer.
    Faria SL; Souhami L; Portelance L; Duclos M; Vuong T; Small D; Freeman CR
    Radiat Oncol; 2006 Nov; 1():42. PubMed ID: 17078878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial.
    Chen M; Chen YY; Bao Y; Xian CG; Liu GZ; Zhang L; Xu GC; Deng XW; Lu TX; Qian JY; Cui NJ
    Clin Lung Cancer; 2005 Mar; 6(5):304-9. PubMed ID: 15845182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
    Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis.
    Hazuka MB; Turrisi AT; Lutz ST; Martel MK; Ten Haken RK; Strawderman M; Borema PL; Lichter AS
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):273-84. PubMed ID: 8407401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.